Harmony Biosciences Holdings (HRMY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.98B
Last updated: Nov 17, 2026 at 11:05 AM ET
Harmony Biosciences Holdings (HRMY) Financials: Revenue, Profit and Cash Flow
Harmony Biosciences Holdings reported revenue of $868.45M for the fiscal year ended Dec 31, 2025, up 21.5% from the year before. That year, net income was $158.69M with a net margin of 18.3%, operating cash flow was $348.20M and free cash flow was $347.89M. The quarter ended Sep 30, 2026 had revenue of $268.92M and net income of $48.20M.
Revenue and Margins
The operating margin was 24.0% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from $6.00M, a compound annual rate of 129.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $868.45M | +21.5% | 77.2% | 24.0% | 18.3% |
| Dec 2024 | $714.73M | +22.8% | 78.1% | 26.7% | 20.4% |
| Dec 2023 | $582.02M | +32.9% | 79.2% | 33.0% | 22.1% |
| Dec 2022 | $437.86M | +43.4% | 80.9% | 27.4% | 41.4% |
| Dec 2021 | $305.44M | +91.2% | 81.8% | 28.7% | 11.3% |
| Dec 2020 | $159.74M | +2564.6% | 82.6% | 10.6% | -23.1% |
| Dec 2019 | $6.00M | N/A | 73.7% | -2433.8% | -2535.1% |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, net income rose 9.1% from the year before. In the quarter ended Sep 2026, net income fell 5.2% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $868.45M | $714.73M | $582.02M | $437.86M | $305.44M | $159.74M | $6.00M | $0 |
| Cost of revenue | $198.34M | $156.81M | $121.24M | $83.48M | $55.52M | $27.74M | $1.58M | $184.00K |
| Gross profit | $670.11M | $557.92M | $460.79M | $354.37M | $249.92M | $132.00M | $4.42M | -$184.00K |
| Research and development | $189.59M | $145.82M | $76.06M | $70.89M | $30.37M | $19.45M | $69.59M | $12.37M |
| Operating income | $208.47M | $190.83M | $192.03M | $120.19M | $87.53M | $16.99M | -$145.90M | -$41.44M |
| Net income | $158.69M | $145.49M | $128.85M | $181.47M | $34.60M | -$36.94M | -$151.98M | -$39.90M |
| EBITDA | $230.76M | $213.04M | $215.59M | $144.97M | $108.62M | $26.56M | -$142.10M | -$41.26M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $268.92M | $261.28M | $215.39M | $243.78M | $239.46M | $200.49M | $184.73M | $201.27M | $186.04M | $172.81M | $154.62M | $168.41M |
| Gross profit | $188.23M | $198.08M | $170.88M | $175.23M | $179.81M | $162.34M | $152.74M | $146.86M | $143.26M | $140.67M | $127.13M | $125.26M |
| Operating income | $54.20M | $89.32M | $37.29M | $38.56M | $65.49M | $48.18M | $56.24M | $55.73M | $61.71M | $21.36M | $52.03M | $40.20M |
| Net income | $48.20M | $75.43M | $32.49M | $22.49M | $50.87M | $39.78M | $45.56M | $49.48M | $46.09M | $11.59M | $38.33M | $26.61M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $163.66M by $588.84M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.27B | $999.20M | $811.45M | $673.87M | $433.44M | $427.07M | $106.70M | $89.28M |
| Current assets | $907.01M | $579.25M | $451.07M | $400.29M | $284.44M | $262.89M | $31.50M | $86.68M |
| Cash and equivalents | $752.50M | $453.00M | $311.66M | $243.78M | $234.31M | $228.63M | $24.46M | $83.52M |
| Total liabilities | $401.41M | $340.05M | $344.46M | $271.03M | $246.94M | $329.89M | $118.29M | $7.75M |
| Short-term debt | $20.00M | $16.25M | $15.00M | $2.00M | $2.00M | $0 | N/A | N/A |
| Long-term debt | $143.66M | $163.02M | $178.57M | $189.65M | $189.98M | $194.25M | $97.95M | N/A |
| Shareholder equity | $870.22M | $659.15M | $466.99M | $402.84M | $186.51M | $97.18M | -$422.86M | $81.53M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.48B | $1.37B | $1.27B | $1.27B | $1.21B | $1.11B | $1.06B | $999.20M | $928.13M | $858.38M | $846.99M | $811.45M |
| Total liabilities | $406.01M | $373.84M | $361.48M | $401.41M | $373.10M | $334.93M | $335.01M | $340.05M | $331.33M | $319.80M | $331.59M | $344.46M |
| Cash and equivalents | $647.10M | $549.77M | $589.40M | $752.50M | $647.00M | $546.05M | $489.00M | $453.00M | $387.37M | $317.30M | $332.98M | $311.66M |
| Shareholder equity | $1.07B | $999.24M | $910.35M | $870.22M | $835.12M | $773.08M | $720.52M | $659.15M | $596.80M | $538.58M | $515.39M | $466.99M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.9% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $348.20M | $219.82M | $219.39M | $144.47M | $98.56M | -$2.98M | -$75.44M | -$38.80M |
| Capital expenditures | $310.00K | $34.22M | $37.28M | $172.00K | $298.00K | $2.00K | $149.00K | $1.34M |
| Free cash flow | $347.89M | $185.60M | $182.11M | $144.29M | $98.26M | -$2.99M | -$75.58M | -$40.14M |
| Dividends paid | N/A | N/A | $5.05M | N/A | N/A | $200.30M | $143.77M | N/A |
| Share repurchases | $0 | $0 | $100.00M | $0 | $300.00K | $167.00K | $0 | N/A |
| Investing cash flow | -$39.65M | -$67.48M | -$46.44M | -$141.83M | -$100.30M | -$2.00M | -$127.15M | -$1.34M |
| Financing cash flow | -$9.05M | -$11.00M | -$105.55M | $6.84M | $7.42M | $209.16M | $143.77M | $21.61M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $76.69M | $92.43M | $27.76M | $126.15M | $108.73M | $79.33M | $33.99M | $75.56M | $70.50M | $42.62M | $31.14M | $76.67M |
| Capital expenditures | N/A | N/A | $0 | $107.00K | $71.00K | $4.00K | $128.00K | $33.58M | $3.00K | $632.00K | $5.00K | $37.07M |
| Free cash flow | N/A | N/A | $27.76M | $126.04M | $108.66M | $79.32M | $33.86M | $41.98M | $70.50M | $41.98M | $31.14M | $39.59M |
Frequently Asked Questions About HRMY
What is Harmony Biosciences Holdings' annual revenue?
Harmony Biosciences Holdings reported revenue of $868.45M for the fiscal year ended Dec 31, 2025.
How fast is Harmony Biosciences Holdings' revenue growing?
Revenue was up 21.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 25.6%.
Is Harmony Biosciences Holdings profitable?
Yes. Harmony Biosciences Holdings reported net income of $158.69M for the fiscal year ended Dec 31, 2025, with a net margin of 18.3%.
How much free cash flow does HRMY generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $348.20M minus capital expenditures of $310.00K produced free cash flow of $347.89M.
How much debt does Harmony Biosciences Holdings have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $143.66M, short-term debt of $20.00M and cash and equivalents of $752.50M.
HRMY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts